97 related articles for article (PubMed ID: 31537542)
1. MicroRNAs Affect Complement Regulator Expression and Mitochondrial Activity to Modulate Cell Resistance to Complement-Dependent Cytotoxicity.
Hillman Y; Mardamshina M; Pasmanik-Chor M; Ziporen L; Geiger T; Shomron N; Fishelson Z
Cancer Immunol Res; 2019 Dec; 7(12):1970-1983. PubMed ID: 31537542
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Complement-Dependent Cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217.
Hillman Y; Mazkereth N; Farberov L; Shomron N; Fishelson Z
J Immunol; 2016 Jun; 196(12):5156-65. PubMed ID: 27183614
[TBL] [Abstract][Full Text] [Related]
3. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement.
Jurianz K; Ziegler S; Donin N; Reiter Y; Fishelson Z; Kirschfink M
Int J Cancer; 2001 Sep; 93(6):848-54. PubMed ID: 11519047
[TBL] [Abstract][Full Text] [Related]
4. Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid.
Donin N; Jurianz K; Ziporen L; Schultz S; Kirschfink M; Fishelson Z
Clin Exp Immunol; 2003 Feb; 131(2):254-63. PubMed ID: 12562385
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells.
Mamidi S; Höne S; Teufel C; Sellner L; Zenz T; Kirschfink M
Oncoimmunology; 2015 Mar; 4(3):e979688. PubMed ID: 25949896
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of complement resistance induced by non-lethal complement attack and by growth arrest.
Marchbank KJ; van den Berg CW; Morgan BP
Immunology; 1997 Apr; 90(4):647-53. PubMed ID: 9176121
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus X protein activates CD59 involving DNA binding and let-7i in protection of hepatoma and hepatic cells from complement attack.
Shan C; Zhang S; Cui W; You X; Kong G; Du Y; Qiu L; Ye L; Zhang X
Carcinogenesis; 2011 Aug; 32(8):1190-7. PubMed ID: 21665888
[TBL] [Abstract][Full Text] [Related]
9. Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.
Loeff FC; van Egmond HME; Nijmeijer BA; Falkenburg JHF; Halkes CJ; Jedema I
Leuk Lymphoma; 2017 Sep; 58(9):1-14. PubMed ID: 28140725
[TBL] [Abstract][Full Text] [Related]
10. Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attack.
Marchbank KJ; Morgan BP; van den Berg CW
Immunology; 1995 May; 85(1):146-52. PubMed ID: 7543447
[TBL] [Abstract][Full Text] [Related]
11. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement.
Reiter Y; Ciobotariu A; Fishelson Z
Eur J Immunol; 1992 May; 22(5):1207-13. PubMed ID: 1577063
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus sensitizes hepatocytes to complement-dependent cytotoxicity through downregulating CD59.
Qu Z; Liang X; Liu Y; Du J; Liu S; Sun W
Mol Immunol; 2009 Dec; 47(2-3):283-9. PubMed ID: 19804910
[TBL] [Abstract][Full Text] [Related]
13. Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis.
Reiter Y; Ciobotariu A; Jones J; Morgan BP; Fishelson Z
J Immunol; 1995 Aug; 155(4):2203-10. PubMed ID: 7636268
[TBL] [Abstract][Full Text] [Related]
14. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.
Livingston PO; Hood C; Krug LM; Warren N; Kris MG; Brezicka T; Ragupathi G
Cancer Immunol Immunother; 2005 Oct; 54(10):1018-25. PubMed ID: 15926079
[TBL] [Abstract][Full Text] [Related]
15. Regulation of complement-dependent cytotoxicity by TGF-β-induced epithelial-mesenchymal transition.
Goswami MT; Reka AK; Kurapati H; Kaza V; Chen J; Standiford TJ; Keshamouni VG
Oncogene; 2016 Apr; 35(15):1888-98. PubMed ID: 26148233
[TBL] [Abstract][Full Text] [Related]
16. [Effect of the expression of glycosylphosphatidylinositol-specific phospholipase D gene on K562 cell sensitivity to complement killing].
Wang YD; Tang JH; Yang ZY; Yu H; Xiang XY
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Dec; 29(6):654-7. PubMed ID: 16114550
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis.
Kraus S; Seger R; Fishelson Z
Clin Exp Immunol; 2001 Mar; 123(3):366-74. PubMed ID: 11298121
[TBL] [Abstract][Full Text] [Related]
18. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.
Mäenpää A; Junnikkala S; Hakulinen J; Timonen T; Meri S
Am J Pathol; 1996 Apr; 148(4):1139-52. PubMed ID: 8644856
[TBL] [Abstract][Full Text] [Related]
19. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms.
Harjunpää A; Junnikkala S; Meri S
Scand J Immunol; 2000 Jun; 51(6):634-41. PubMed ID: 10849376
[TBL] [Abstract][Full Text] [Related]
20. [Screening for drug resistance related microRNAs in K562 and K562/A02 cell lines].
Cao YX; Dai CW; Zhang GS
Zhonghua Xue Ye Xue Za Zhi; 2010 Jun; 31(6):361-5. PubMed ID: 21122348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
